The Xpert Bladder Cancer Monitor test for the GeneXpert system has a high negative predictive value and provides results non-invasively in about 90 minutes.
The urine-based test combines massively parallel sequencing with proprietary error-reducing technology developed at Johns Hopkins.
The University of Minnesota's Shilpa Gupta will work with Biocept on a study aimed at providing clinical support for the use of the firm's PD-L1 and AR tests.
In the second half of the year, the firm plans to introduce a urine-based bladder cancer test and achieve sales growth between 30 and 50 percent.
The company plans to launch its first bladder cancer test in the second half of the year, and is in the early stages of validating a third test for prostate cancer.
The test may help identify patients most likely to respond to Roche's new metastatic urothelial cancer drug Tecentriq, the FDA said.
Both institutions aim to develop novel liquid biopsy approaches that would improve physicians' ability to diagnose, monitor, and treat cancer patients.
The Horizon 2020 grant will help the Israeli firm commercially develop its noninvasive DNA methylation-based tests for cancer screening and monitoring.
The company said revenues from its ConfirmMDx prostate cancer test rose 62 percent in 2015, and that testing volume exceeded 15,000 patients.
Researchers and clinicians attempting to select targeted therapies must take sample heterogeneity into account.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.
A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.
Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.
Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.